Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Targovax ASA ( (GB:0RIS) ).
Circio Holding ASA has reminded investors that trading in subscription rights for its ongoing rights issue of up to NOK 50 million, listed under the ticker CRNAT, will end today at 16:30 CET, with any rights not traded or exercised by the close of the subscription period on 29 January 2026 lapsing without value. The company has already secured NOK 44.2 million of the targeted proceeds through a combination of pre-subscriptions and underwriting commitments, underscoring strong support for the capital raising that is expected to strengthen its financial position as it advances its circular RNA platform and immuno-oncology pipeline.
More about Targovax ASA
Circio Holding ASA is a biotechnology company developing novel circular RNA (circRNA) expression technology for use in gene and cell therapies. Its proprietary circVec platform is designed to deliver significantly extended RNA half-life and enhanced protein expression compared with conventional mRNA-based viral and non-viral vector systems, targeting applications across genetic medicine, cell therapy and chronic disease. The company also continues to advance its legacy immuno-oncology program TG01, a peptide vaccine targeting RAS-mutated cancers that is currently being evaluated in clinical trials in Norway and the United States.
Average Trading Volume: 3,979,855
Current Market Cap: NOK204.9M
See more insights into 0RIS stock on TipRanks’ Stock Analysis page.